Glutamine Supplementation Alleviates Vasculopathy and Corrects Metabolic Profile in an In Vivo Model of Endothelial Cell Dysfunction

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Addabbo, Francesco ^a,b   Chen, Qiuying ^c   Patel, Dhara P ^a   Rabadi, May ^a   Ratliff, Brian ^a   Zhang, Frank ^a   Jasmin, Jean Francois ^d   Wolin, Michael ^a   Lisanti, Michael ^d,e   Gross, Steven S ^c   Goligorsky, Michael S ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b National Institute of Gastroenterology   (Italy)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; CAVEOLIN 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTAMINE; HIPPURIC ACID; N(G) METHYLARGININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTERY DILATATION; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENZYME INACTIVATION; EX VIVO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLIC REGULATION; MOUSE; NONHUMAN; TRANSGENIC MOUSE; TREATMENT OUTCOME; VASCULAR DISEASE; VASCULAR RING; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA; ENDOTHELIAL CELLS; GLUTAMINE; MALE; MICE; OMEGA-N-METHYLARGININE; VASODILATION;

ANIMALIA; MUS; MUS MUSCULUS;

EID: 84878947210     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065458     Document Type: Article

References (54)

1. Vita JA, Keaney JF Jr, (2002) Endothelial function: a barometer for cardiovascular risk? Circulation 106: 640-642.
2. Lindner A, Charra B, Sherrard DJ, Scribner BH, (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. The New England journal of medicine 290: 697-701.
3. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, et al. (1998) Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. American journal of kidney diseases: the official journal of the National Kidney Foundation 32: 853-906.
4. Goligorsky MS, (2005) Endothelial cell dysfunction: can't live with it, how to live without it. American journal of physiology Renal physiology 288: F871-880.
5. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, et al. (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117.
6. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, et al. (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358: 2127-2128.
7. Vallance P, (2001) Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 358: 2096-2097.
8. Vallance P, Leiper J, (2004) Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arteriosclerosis, thrombosis, and vascular biology 24: 1023-1030.
9. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, et al. (2003) Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arteriosclerosis, thrombosis, and vascular biology 23: 1455-1459.
10. Noiri E, Lee E, Testa J, Quigley J, Colflesh D, et al. (1998) Podokinesis in endothelial cell migration: role of nitric oxide. The American journal of physiology 274: C236-244.
11. Goligorsky MS, Abedi H, Noiri E, Takhtajan A, Lense S, et al. (1999) Nitric oxide modulation of focal adhesions in endothelial cells. The American journal of physiology 276: C1271-1281.
12. Goligorsky MS, Noiri E, Tsukahara H, Budzikowski AS, Li H, (2000) A pivotal role of nitric oxide in endothelial cell dysfunction. Acta physiologica Scandinavica 168: 33-40.
13. Abu-Soud HM, Feldman PL, Clark P, Stuehr DJ, (1994) Electron transfer in the nitric-oxide synthases. Characterization of L-arginine analogs that block heme iron reduction. The Journal of biological chemistry 269: 32318-32326.
14. Addabbo F, Ratliff B, Park HC, Kuo MC, Ungvari Z, et al. (2009) The Krebs cycle and mitochondrial mass are early victims of endothelial dysfunction: proteomic approach. The American journal of pathology 174: 34-43.
15. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
16. Wischmeyer PE, (2007) Glutamine: mode of action in critical illness. Critical care medicine 35: S541-544.
17. Wernerman J, (2008) Clinical use of glutamine supplementation. The Journal of nutrition 138: 2040S-2044S.
18. Wernerman J, (2008) Role of glutamine supplementation in critically ill patients. Current opinion in anaesthesiology 21: 155-159.
19. Coeffier M, Dechelotte P, (2005) The role of glutamine in intensive care unit patients: mechanisms of action and clinical outcome. Nutrition reviews 63: 65-69.
20. Parry-Billings M, Evans J, Calder PC, Newsholme EA, (1990) Does glutamine contribute to immunosuppression after major burns? Lancet 336: 523-525.
21. Wilmore DW (2001) The effect of glutamine supplementation in patients following elective surgery and accidental injury. The Journal of nutrition 131: 2543S-2549S; discussion 2550S-2541S.
22. Roth E, (2008) Nonnutritive effects of glutamine. The Journal of nutrition 138: 2025S-2031S.
23. Ziegler TR, Benfell K, Smith RJ, Young LS, Brown E, et al. (1990) Safety and metabolic effects of L-glutamine administration in humans. JPEN Journal of parenteral and enteral nutrition 14: 137S-146S.
24. Brunengraber H, Roe CR, (2006) Anaplerotic molecules: current and future. Journal of inherited metabolic disease 29: 327-331.
25. Owen OE, Kalhan SC, Hanson RW, (2002) The key role of anaplerosis and cataplerosis for citric acid cycle function. The Journal of biological chemistry 277: 30409-30412.
26. O'Riordan E, Mendelev N, Patschan S, Patschan D, Eskander J, et al. (2007) Chronic NOS inhibition actuates endothelial-mesenchymal transformation. American journal of physiology Heart and circulatory physiology 292: H285-294.
27. Stoessel A, Paliege A, Theilig F, Addabbo F, Ratliff B, et al. (2008) Indolent course of tubulointerstitial disease in a mouse model of subpressor, low-dose nitric oxide synthase inhibition. American journal of physiology Renal physiology 295: F717-725.
28. Linder AE, Weber DS, Whitesall SE, D'Alecy LG, Webb RC, (2005) Altered vascular reactivity in mice made hypertensive by nitric oxide synthase inhibition. Journal of cardiovascular pharmacology 46: 438-444.
29. Chen Q, Park HC, Goligorsky MS, Chander P, Fischer SM, et al. (2012) Untargeted plasma metabolite profiling reveals the broad systemic consequences of xanthine oxidoreductase inactivation in mice. PloS one 7: e37149.
30. Feron O, Saldana F, Michel JB, Michel T, (1998) The endothelial nitric-oxide synthase-caveolin regulatory cycle. The Journal of biological chemistry 273: 3125-3128.
31. Hassan GS, Jasmin JF, Schubert W, Frank PG, Lisanti MP, (2004) Caveolin-1 deficiency stimulates neointima formation during vascular injury. Biochemistry 43: 8312-8321.
32. Tourkina E, Richard M, Gooz P, Bonner M, Pannu J, et al. (2008) Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. American journal of physiology Lung cellular and molecular physiology 294: L843-861.
33. Park HC, Yasuda K, Ratliff B, Stoessel A, Sharkovska Y, et al. (2010) Postobstructive regeneration of kidney is derailed when surge in renal stem cells during course of unilateral ureteral obstruction is halted. American journal of physiology Renal physiology 298: F357-364.
34. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, et al. (2001) Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. The Journal of biological chemistry 276: 38121-38138.
35. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, et al. (2003) Review on uremic toxins: classification, concentration, and interindividual variability. Kidney international 63: 1934-1943.
36. Shanware NP, Mullen AR, DeBerardinis RJ, Abraham RT, (2011) Glutamine: pleiotropic roles in tumor growth and stress resistance. Journal of molecular medicine 89: 229-236.
37. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, et al. (2008) Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111: 402-410.
38. Murphy C, Newsholme P, (1998) Importance of glutamine metabolism in murine macrophages and human monocytes to L-arginine biosynthesis and rates of nitrite or urea production. Clinical science 95: 397-407.
39. Bogle RG, Baydoun AR, Pearson JD, Mann GE, (1996) Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. The Journal of physiology 490 (Pt 1): 229-241.
40. Swierkosz TA, Mitchell JA, Sessa WC, Hecker M, Vane JR, (1990) L-glutamine inhibits the release of endothelium-derived relaxing factor from the rabbit aorta. Biochemical and biophysical research communications 172: 143-148.
41. Sessa WC, Hecker M, Mitchell JA, Vane JR, (1990) The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 87: 8607-8611.
42. Arnal JF, Munzel T, Venema RC, James NL, Bai CL, et al. (1995) Interactions between L-arginine and L-glutamine change endothelial NO production. An effect independent of NO synthase substrate availability. The Journal of clinical investigation 95: 2565-2572.
43. Schachter D, (2007) L-glutamine in vitro regulates rat aortic glutamate content and modulates nitric oxide formation and contractility responses. American journal of physiology Cell physiology 293: C142-151.
44. Xu H, Pearl RG, (1994) Effect of l-glutamine on pulmonary hypertension in the perfused rabbit lung. Pharmacology 48: 260-264.
45. Hayashi Y, Sawa Y, Fukuyama N, Nakazawa H, Matsuda H, (2002) Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circulation 106: 2601-2607.
46. Gorg B, Wettstein M, Metzger S, Schliess F, Haussinger D, (2005) Lipopolysaccharide-induced tyrosine nitration and inactivation of hepatic glutamine synthetase in the rat. Hepatology 41: 1065-1073.
47. Mutsaers HA, van den Heuvel LP, Ringens LH, Dankers AC, Russel FG, et al. (2011) Uremic toxins inhibit transport by breast cancer resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PloS one 6: e18438.
48. Spustova V, Dzurik R, Gerykova M, (1987) Hippurate participation in the inhibition of glucose utilization in renal failure. Czechoslovak medicine 10: 79-89.
49. Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, et al. (2003) Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Experimental nephrology 95: e111-118.
50. Deguchi T, Takemoto M, Uehara N, Lindup WE, Suenaga A, et al. (2005) Renal clearance of endogenous hippurate correlates with expression levels of renal organic anion transporters in uremic rats. The Journal of pharmacology and experimental therapeutics 314: 932-938.
51. Ciborowski M, Martin-Ventura JL, Meilhac O, Michel JB, Ruperez FJ, et al. (2011) Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. Journal of proteome research 10: 1374-1382.
52. Krebs HA, Hems R, Weidemann MJ, Speake RN, (1966) The fate of isotopic carbon in kidney cortex synthesizing glucose from lactate. The Biochemical journal 101: 242-249.
53. Jeong SM, Xiao C, Finley LW, Lahusen T, Souza AL, et al. (2013) SIRT4 Has Tumor-Suppressive Activity and Regulates the Cellular Metabolic Response to DNA Damage by Inhibiting Mitochondrial Glutamine Metabolism. Cancer Cell 23: 450-463.
54. Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, et al. (2013) The B55alpha Subunit of PP2A Drives a p53-Dependent Metabolic Adaptation to Glutamine Deprivation. Mol Cell 50: 200-211.